KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATFurniture, Fixtures and OtherLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShort-Term Debt repayments
Ratios

Boston Scientific (BSX) EBIAT (2016 - 2025)

Boston Scientific's EBIAT history spans 17 years, with the latest figure at $669.0 million for Q4 2025.

  • For Q4 2025, EBIAT rose 19.04% year-over-year to $669.0 million; the TTM value through Dec 2025 reached $2.9 billion, up 56.61%, while the annual FY2025 figure was $2.9 billion, 56.66% up from the prior year.
  • EBIAT for Q4 2025 was $669.0 million at Boston Scientific, down from $755.0 million in the prior quarter.
  • Across five years, EBIAT topped out at $795.0 million in Q2 2025 and bottomed at $93.0 million in Q4 2021.
  • The 5-year median for EBIAT is $380.0 million (2021), against an average of $403.2 million.
  • The largest annual shift saw EBIAT soared 3000.0% in 2021 before it plummeted 67.74% in 2022.
  • A 5-year view of EBIAT shows it stood at $93.0 million in 2021, then surged by 50.54% to $140.0 million in 2022, then skyrocketed by 260.0% to $504.0 million in 2023, then rose by 11.51% to $562.0 million in 2024, then grew by 19.04% to $669.0 million in 2025.
  • Per Business Quant, the three most recent readings for BSX's EBIAT are $669.0 million (Q4 2025), $755.0 million (Q3 2025), and $795.0 million (Q2 2025).